Boswellia serrata,
does it really help with Reduced asthma attacks, dyspnea, and wheeze with improved lung function?
research showsA 1998 six-week double-blind placebo-controlled trial gave Boswellia gum resin 300 mg three times daily and reported improvement in 70% of 20 treated patients versus 27% of 20 controls. This remains a small, old, isolated trial. A later systematic review highlighted short duration, poor methods, and weak agreement between symptoms and objective outcomes across herbal asthma trials, with no independent replication for Boswellia. Claims for attacks, dyspnea, wheeze, and FEV1 are therefore graded D.
ads claimMarketing can expand an anti-inflammatory mechanism and one 1998 study into guaranteed attack prevention or replacement of inhaled corticosteroids. Reliance on a supplement during an acute exacerbation can delay proven rescue treatment.
Useful facts when choosing a product
- This verdict concerns bronchial asthma and is separate from Boswellia verdicts for joint pain or ulcerative colitis.
- The pivotal trial used gum resin 300 mg three times daily for six weeks; commercial standardized extracts are not necessarily equivalent.
- Gastrointestinal upset and liver-enzyme abnormalities can occur, and avoidance during pregnancy is prudent. Potential interaction should be reviewed in people taking anticoagulant or antiplatelet medicines.
Chamgap Semantic Classification Code
Candidate index · review held
S.boswellia-serrata.oral.asthma-attacks-dyspnea-and-wheeze-with-improved-lung-function.reduce.placeboSupplements and nutraceuticals > Boswellia serrata > Oral > asthma attacks, dyspnea, and wheeze with improved lung function > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The Gupta trial assigned 80 people with bronchial asthma to Boswellia gum resin 300 mg three times daily or lactose placebo for six weeks. About 70% of the 40 treated participants and 27% of the 40 controls reportedly improved in symptoms, physical signs, and measures including FEV1. The 2010 Clark review evaluated 26 herbal trials and found Boswellia showed potential for lung function in a single study, but symptom improvements were not strongly supported by objective change and most studies were small, short, and methodologically poor.
Why this is classified as D (31)
An isolated positive 40-person, six-week trial lacks independent replication, while systematic review identified small samples, short duration, poor methods, and weak objective support. The grade is D with 31 points.
Counterpoint. Validated controller therapy, including inhaled corticosteroids, and an asthma action plan remain priorities; Boswellia must not replace prescribed or rescue medication.
Rejudgment record. New verdict — The positive signal from a 40-person, six-week double-blind trial was accepted, but absent independent replication and systematic-review findings of small, short, methodologically poor trials with weak objective support require D under rule ②
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced frequency of asthma attacks | D | Only one small six-week trial provides a signal, without independent replication of exacerbation frequency. |
| Improved dyspnea and wheeze | D | Subjective symptom improvement was reported, but trial quality and reproducibility are poor. |
| Improved lung function including FEV1 | D | The positive result from one trial has not been reproduced in a standardized contemporary study. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gupta I et al. 1998 | Six-week double-blind placebo-controlled clinical trial | 40 | Inadequately reported | Attacks, dyspnea, wheeze, physical signs, and FEV1 | Improvement was reported in 14 of 20 treated participants and 5 of 20 controls. | Only direct positive trial; small and old |
| Clark CE et al. 2010 | Systematic review and meta-analysis of herbal asthma interventions | 20 | Academic and Cochrane-collaborative research | Lung function, exacerbations, steroid reduction, and symptoms | Boswellia showed potential in one study, but most evidence was small, short, and poor quality, preventing recommendations. | Key synthesis of replication and quality limitations |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Final verification and publication gate: Codex · Verification cutoff: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Boswellia serrata x bronchial-asthma symptoms and lung function — Evidence Grade D·31. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/boswellia-serrata-bronchial-asthma-symptoms-lung-function/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.